Literature DB >> 33506054

Reduced Expression of Antimicrobial Protein Secretory Leukoprotease Inhibitor and Clusterin in Chronic Rhinosinusitis with Nasal Polyps.

Yanran Huang1,2, Ming Wang1,2, Yu Hong1,2, Xiangting Bu1,2, Ge Luan1,2, Yang Wang1,2, Ying Li1,2, Hongfei Lou1, Chengshuo Wang1, Luo Zhang1,2,3.   

Abstract

INTRODUCTION: Antimicrobial peptides and proteins (AMPs) constitute the first line of defense against pathogenic microorganisms in the airway. The association between AMPs and chronic rhinosinusitis with nasal polyps (CRSwNP) requires further investigations. This study is aimed at investigating the expression and regulation of major dysregulated AMPs in the nasal mucosa of CRSwNP.
METHODS: The expression of AMPs was analyzed in nasal tissue from patients with eosinophilic (E) CRSwNP and nonECRSwNP and healthy subjects using RNA sequencing. The 10 most abundant AMPs expressed differentially in CRSwNP patients were verified by real-time PCR, and of these, the expression and regulation of secretory leukoprotease inhibitor (SLPI) and clusterin (CLU) were investigated further.
RESULTS: The 10 most abundant AMPs expressed differentially in CRSwNP compared to healthy control, regardless of subtypes, included BPIFA1, BPIFB1, BPIFB2, CLU, LTF, LYZ, and SLPI, which were downregulated, and S100A8, S100A9, and HIST1H2BC, which were upregulated. ELISA and immunofluorescence confirmed the decreased expression of SLPI and CLU levels in CRSwNP. SLPI is expressed in both nasal epithelial cells and glandular cells, whereas CLU is mainly expressed in glandular cells. AB/PAS staining further demonstrated that both SLPI and CLU were mainly produced by mucous cells in submucosal glands. Furthermore, the numbers of submucosal glands were significantly decreased in nasal polyp tissue of CRSwNP compared to nasal tissue of controls. SLPI was downregulated by TGF-β1 and IL-4 in cultured nasal tissues in vitro, while CLU expression was inhibited by TGF-β1. Glucocorticoid treatment for 2 weeks significantly increased the expression of all downregulated AMPs, but not LYZ. Additionally, budesonide significantly increased the expression of SLPI and CLU in cultured nasal tissues.
CONCLUSION: The expression of major antimicrobial proteins is significantly decreased in nasal tissue of CRSwNP. The expression of SLPI and CLU is correlated with the numbers of submucosal glands and regulated by inflammatory cytokines and glucocorticoids.
Copyright © 2021 Yanran Huang et al.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33506054      PMCID: PMC7810533          DOI: 10.1155/2021/1057186

Source DB:  PubMed          Journal:  J Immunol Res        ISSN: 2314-7156            Impact factor:   4.818


  55 in total

1.  Corticosteroid treatment regulates mucosal remodeling in chronic rhinosinusitis with nasal polyps.

Authors:  Francisco de Borja Callejas; Asunción Martínez-Antón; César Picado; Isam Alobid; Laura Pujols; Antonio Valero; Jordi Roca-Ferrer; Joaquim Mullol
Journal:  Laryngoscope       Date:  2015-01-13       Impact factor: 3.325

Review 2.  The role of human β-defensins in allergic diseases.

Authors:  F Niyonsaba; C Kiatsurayanon; H Ogawa
Journal:  Clin Exp Allergy       Date:  2016-11-16       Impact factor: 5.018

3.  TGF-β1 Impairs Vitamin D-Induced and Constitutive Airway Epithelial Host Defense Mechanisms.

Authors:  Jasmijn A Schrumpf; Dennis K Ninaber; Anne M van der Does; Pieter S Hiemstra
Journal:  J Innate Immun       Date:  2019-04-10       Impact factor: 7.349

4.  The effects of corticosteroid on tissue lactoferrin in patients with nasal polyposis.

Authors:  Engin Acıoğlu; Ozgür Yigit; Zeynep Alkan; Elad Azizli; Ramisa Gelişgen; Hafize Uzun
Journal:  Am J Rhinol Allergy       Date:  2012 Jan-Feb       Impact factor: 2.467

5.  Reduced expression of antimicrobial PLUNC proteins in nasal polyp tissues of patients with chronic rhinosinusitis.

Authors:  S Seshadri; D C Lin; M Rosati; R G Carter; J E Norton; L Suh; A Kato; R K Chandra; K E Harris; H W Chu; A T Peters; B K Tan; D B Conley; L C Grammer; R C Kern; R P Schleimer
Journal:  Allergy       Date:  2012-07       Impact factor: 13.146

6.  Defective epithelial barrier in chronic rhinosinusitis: the regulation of tight junctions by IFN-γ and IL-4.

Authors:  Michael B Soyka; Paulina Wawrzyniak; Thomas Eiwegger; David Holzmann; Angela Treis; Kerstin Wanke; Jeannette I Kast; Cezmi A Akdis
Journal:  J Allergy Clin Immunol       Date:  2012-07-26       Impact factor: 10.793

7.  Human cathelicidin antimicrobial peptide is up-regulated in the eosinophilic mucus subgroup of chronic rhinosinusitis patients.

Authors:  Eng Hooi Ooi; Peter-John Wormald; A Simon Carney; Craig Lloyd James; Lor Wai Tan
Journal:  Am J Rhinol       Date:  2007 Jul-Aug

8.  Comparative analysis of inflammatory signature profiles in eosinophilic and noneosinophilic chronic rhinosinusitis with nasal polyposis.

Authors:  Yao Yao; Chunguang Yang; Xing Yi; Shaobing Xie; Hong Sun
Journal:  Biosci Rep       Date:  2020-02-28       Impact factor: 3.840

Review 9.  Highlights of eosinophilic chronic rhinosinusitis with nasal polyps in definition, prognosis, and advancement.

Authors:  Hongfei Lou; Nan Zhang; Claus Bachert; Luo Zhang
Journal:  Int Forum Allergy Rhinol       Date:  2018-10-08       Impact factor: 3.858

Review 10.  Host-microbial interactions in patients with chronic rhinosinusitis.

Authors:  Daniel L Hamilos
Journal:  J Allergy Clin Immunol       Date:  2013-11-28       Impact factor: 10.793

View more
  2 in total

1.  Strong and consistent associations of precedent chronic rhinosinusitis with risk of non-cystic fibrosis bronchiectasis.

Authors:  Brian S Schwartz; Saba A Al-Sayouri; Jonathan S Pollak; Annemarie G Hirsch; Robert Kern; Bruce Tan; Atsushi Kato; Robert P Schleimer; Anju T Peters
Journal:  J Allergy Clin Immunol       Date:  2022-03-18       Impact factor: 14.290

2.  Transcriptomic and Lipidomic Profiles in Nasal Polyps of Glucocorticoid Responders and Non-Responders: Before and After Treatment.

Authors:  Zhenzhen Zhu; Weiqing Wang; Yang Zha; Xiaowei Wang; Lei Wang; Jinbo Han; Jianmin Zhang; Wei Lv
Journal:  Front Pharmacol       Date:  2022-01-13       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.